Biodesix Inc Stock News

Grew full-year revenue to an estimated $71.3 million, an increase of 45% Grew full-year revenue to an estimated $71.3 million, an increase of 45%

Analysis of 447 patients receiving the Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal reaffirms test performance Analysis of 447 patients receiving the Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal reaffirms test performance

Biodesix, Inc. (NASDAQ:BDSX ) Q3 2024 Earnings Conference Call November 1, 2024 8:30 AM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Kyle Mikson - Canaccord Genuity Dan Brennan - TD Cowen Sung Ji Nam - Scotia Bank Bill Bonello - Craig-Ha...

Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m. ET LOUISVILLE, Colo.

LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will participate in three upcoming investor conferences:

LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30, 2024 before the start of trading on Friday, November 1. Biodesix management will host a conference call and webcast to discuss its financial results and provide a g...

LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2024 in Boston, Massachusetts on Tuesday, October 8 at 10:20 am ET. The presentation will detail the experience of healthcare providers using the Nodify Lung® Nodule Risk Assessment in ...

Biodesix, Inc. (NASDAQ:BDSX ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Chris Brinzey - IR Scott Hutton - CEO Robin Harper Cowie - CFO Conference Call Participants Andrew Brackmann - William Blair Thomas Flaten - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to the Biodesix Q2 2024 Earnings Conference Call.